"Our strong partnership with WHO and C-TAP partners has been essential in negotiating this licence, and I look forward to our continued collaboration, drawing on WHO’s expertise and guidance going forward,” said Charles Gore, Executive Director of MPP.
“What is clear is that MPP's model can work across different health technologies, and we are thrilled to be signing our first C-TAP/MPP test licence with CSIC."
Dr. Rosa Menéndez, president of CSIC, emphasized how important it is to seek solutions so that technologies related to the COVID-19 pandemic in particular, and health in general, reach all countries, including those most in need.
“In this sense, we would like this action by CSIC, of taking part in the international initiatives of MPP and WHO, to become an example and a reference for other research organizations in the world.”
12765
迄今为止，已有四种不同的检测技术，其中一种有可能区分COVID-19感染者与疫苗接种者的免疫反应。
The technology to date has resulted in four different tests, one of which has the potential to distinguish the immune response of COVID-19 infected individuals from vaccinated individuals.
12766
这应该有助于进一步研究免疫水平和免疫时间以及我们所掌握的工具的有效性。
This should aid further research into the level and length of immunity and the efficacy of the tools at our disposal.
The tests are simple to use and suitable for all settings with a basic laboratory infrastructure, such as those found in rural areas in low- and middle-income countries.
The reading can theoretically be done manually (with naked eye comparing the colour of the wells against the colour chart), but an ELISA reader is recommended for greater accuracy of results.
Promising performance data in the European population will need to be supplemented by the companies that will produce this technology if they plan to sell the test in low- and middle-income countries.